

Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2020

<https://marketpublishers.com/r/D0552D6AE7FEN.html>

Date: September 2020

Pages: 35

Price: US\$ 2,000.00 (Single User License)

ID: D0552D6AE7FEN

Abstracts

Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Deep Vein Thrombosis - Pipeline Review, H2 2020, provides an overview of the Deep Vein Thrombosis (Cardiovascular) pipeline landscape.

Deep venous thrombosis is a blood clot that forms in a vein deep inside a part of the body. It mainly affects the large veins in the lower leg and thigh. Symptoms include changes in skin color (redness), leg pain, leg swelling (edema) and skin that feels warm to the touch. The predisposing factors include age, smoking, inheriting a blood-clotting disorder, injury or surgery, cancer, inflammatory bowel disease and heart failure.

Treatment includes thrombolytic and anticoagulants.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Deep Vein Thrombosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Deep Vein Thrombosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Deep Vein Thrombosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Deep Vein Thrombosis (DVT) and features dormant and discontinued projects. The guide covers therapeutics under Development

by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I and Preclinical stages are 1, 1, 2 and 4 respectively.

Deep Vein Thrombosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Deep Vein Thrombosis (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Deep Vein Thrombosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Deep Vein Thrombosis (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Deep Vein Thrombosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Deep Vein Thrombosis (Cardiovascular)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Deep Vein Thrombosis (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Deep Vein Thrombosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Deep Vein Thrombosis (DVT) - Overview

Deep Vein Thrombosis (DVT) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Deep Vein Thrombosis (DVT) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Deep Vein Thrombosis (DVT) - Companies Involved in Therapeutics Development

CarboMimetics

Chengdu Easton Biopharmaceuticals Co Ltd

Glycan Therapeutics Inc

Laboratorios Farmaceuticos Rovi SA

Marizyme Inc

Protheragen Inc

Tianjin Pharmaceuticals Group Co Ltd

Valeo Pharma Inc

Deep Vein Thrombosis (DVT) - Drug Profiles

CM-20201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CX-3002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enoxaparin sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MB-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polysaccharide to Inhibit Coagulation Factor X for Deep Vein Thrombosis and Sickle Cell Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Redesca - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit NMMHC IIA for Deep Vein Thrombosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Zifa-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Deep Vein Thrombosis (DVT) - Dormant Projects

Deep Vein Thrombosis (DVT) - Discontinued Products

Deep Vein Thrombosis (DVT) - Product Development Milestones

Featured News & Press Releases

Nov 14, 2019: Valeo Pharma announces filing of a New Drug Submission for Low Molecular Weight Heparin in Canada

Sep 19, 2018: ROVI has commenced the marketing of its enoxaparin biosimilar in Spain

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Deep Vein Thrombosis (DVT), H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Deep Vein Thrombosis (DVT) - Pipeline by CarboMimetics, H2 2020

Deep Vein Thrombosis (DVT) - Pipeline by Chengdu Easton Biopharmaceuticals Co Ltd, H2 2020

Deep Vein Thrombosis (DVT) - Pipeline by Glycan Therapeutics Inc, H2 2020

Deep Vein Thrombosis (DVT) - Pipeline by Laboratorios Farmaceuticos Rovi SA, H2 2020

Deep Vein Thrombosis (DVT) - Pipeline by Marizyme Inc, H2 2020

Deep Vein Thrombosis (DVT) - Pipeline by Protheragen Inc, H2 2020

Deep Vein Thrombosis (DVT) - Pipeline by Tianjin Pharmaceuticals Group Co Ltd, H2 2020

Deep Vein Thrombosis (DVT) - Pipeline by Valeo Pharma Inc, H2 2020

Deep Vein Thrombosis (DVT) - Dormant Projects, H2 2020

Deep Vein Thrombosis (DVT) - Dormant Projects, H2 2020 (Contd..1), H2 2020

Deep Vein Thrombosis (DVT) - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Deep Vein Thrombosis (DVT), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products by Targets, H2 2020

Number of Products by Stage and Targets, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

CarboMimetics

Chengdu Easton Biopharmaceuticals Co Ltd

Glycan Therapeutics Inc

Laboratorios Farmaceuticos Rovi SA

Marizyme Inc

Protheragen Inc

Tianjin Pharmaceuticals Group Co Ltd

Valeo Pharma Inc

I would like to order

Product name: Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/D0552D6AE7FEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D0552D6AE7FEN.html>